{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:07:28Z","timestamp":1793142448552,"version":"4.5.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This study evaluated the neurotoxicity of ADCs using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><jats:p><jats:bold>Research design and methods:<\/jats:bold> Data were extracted from the FAERS database for 2004 Q1 to 2022 Q4. We analysed the clinical characteristics of ADC-related neurological adverse events (AEs). We used the reporting odds ratio (ROR) and proportional reporting ratio (PRR) for the disproportionality analysis to evaluate the potential association between AEs and ADCs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 562 cases of neurological AEs were attributed to ADCs. The median age was 65\u00a0years old [(Min; Max) = 3; 92]. Neurotoxic signals were detected in patients receiving brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, trastuzumab emtansine, gemtuzumab ozogamicin, inotuzumab ozogamicin, and trastuzumab deruxtecan. The payloads of brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, and trastuzumab emtansine were microtubule polymerization inhibitors, which are more likely to develop neurotoxicity. We also found that brentuximab vedotin- and gemtuzumab ozogamicin-related neurological AEs were more likely to result in serious outcomes. The eight most common ADC-related nervous system AE signals were peripheral neuropathy [ROR (95% CI) = 16.98 (14.94\u201319.30), PRR (95% CI) = 16.0 (14.21\u201318.09)], cerebral haemorrhage [ROR (95% CI) = 9.45 (7.01\u201312.73), PRR (95% CI) = 9.32 (6.95\u201312.50)], peripheral sensory neuropathy [ROR (95% CI) = 47.87 (33.13\u201369.19), PRR (95% CI) = 47.43 (32.93\u201368.30)], polyneuropathy [ROR (95% CI) = 26.01 (18.61\u201336.33), PRR (95% CI) = 25.75 (18.50\u201335.86)], encephalopathy [ROR (95% CI) = 5.16 (3.32\u20138.01), PRR (95% CI) = 5.14 (3.32\u20137.96)], progressive multifocal leukoencephalopathy [ROR (95% CI) = 22.67 (14.05\u201336.58), PRR (95% CI) = 22.52 (14.01\u201336.21)], taste disorder [ROR (95% CI) = 26.09 (15.92\u201342.76), PRR (95% CI) = 25.78 (15.83\u201342.00)], and guillain barrier syndrome [ROR (95% CI) = 17.844 (10.11\u201331.51), PRR (95% CI) = 17.79 (10.09\u201331.35)]. The mortality rate appeared to be relatively high concomitantly with AEs in the central nervous system.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> ADCs may increase the risk of neurotoxicity in cancer patients, leading to serious mortality. With the widespread application of newly launched ADC drugs, combining the FAERS data with other data sources is crucial for monitoring the neurotoxicity of ADCs. Further studies on the potential mechanisms and preventive measures for ADC-related neurotoxicity are necessary.<\/jats:p>","DOI":"10.3389\/fphar.2024.1362484","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:31:35Z","timestamp":1707280295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"15","author":[{"given":"Linlin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","article-title":"Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues","volume":"18","author":"Bae","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"Bohm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.psychres.2023.115300","article-title":"Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS","volume":"326","author":"Chen","year":"2023","journal-title":"Psychiatry Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E103","DOI":"10.1188\/18.CJON.E103-E114","article-title":"Brentuximab vedotin: a nursing perspective on best practices and management of associated adverse events","volume":"22","author":"Clifford","year":"2018","journal-title":"Clin. J. Oncol. Nurs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/abt\/tbab005","article-title":"Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities","volume":"4","author":"Endo","year":"2021","journal-title":"Antib. Ther."},{"key":"B14","unstructured":"BESPONSA (inotuzumab ozogamicin)2017"},{"key":"B15","unstructured":"LUMOXITI\u00ae (moxetumomab pasudotox-tdfk)"},{"key":"B16","unstructured":"MYLOTARGTM (gemtuzumab ozogamicin)"},{"key":"B17","unstructured":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki)"},{"key":"B18","unstructured":"KADCYLATM(ado-trastuzumab emtansin)"},{"key":"B19","unstructured":"KADCYLA\u00ae (ado-trastuzumab emtansine)"},{"key":"B20","unstructured":"ZYNLONTA\u00ae (loncastuximab tesirine-lpyl)"},{"key":"B21","unstructured":"ADCETRIS\u00ae (brentuximab vedotin)"},{"key":"B22","unstructured":"TIVDAK\u00ae (tisotumab vedotin-tftv)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","article-title":"Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study","volume":"47","author":"Guo","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jnen\/nlaa099","article-title":"Multifocal necrotizing leukoencephalopathy with preferential microglia toxicity in a patient treated with chimeric antigen receptor T-cells and review of the literature","volume":"79","author":"Marker","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. New Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","article-title":"Axonal transport defects in neurodegenerative diseases","volume":"29","author":"Morfini","year":"2009","journal-title":"J. Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2147\/DDDT.S267404","article-title":"Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety","volume":"15","author":"Offidani","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pds.2014","article-title":"Selected control events and reporting odds ratio in signal detection methodology","volume":"19","author":"Ooba","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863276447231108092936","article-title":"Identification of novel signals associated with US-FDA approved drugs (2013) using disproportionality analysis","volume":"19","author":"Raghuvanshi","year":"2023","journal-title":"Curr. Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yrtph.2016.10.012","article-title":"Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: challenges and perspectives in translatability from nonclinical toxicology studies to the clinic","volume":"82","author":"Stagg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","author":"Sun","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2023.2248876","article-title":"A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database","author":"Tang","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"53","author":"Wagner-Johnston","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:31:38Z","timestamp":1707280298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":54,"alternative-id":["10.3389\/fphar.2024.1362484"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1362484","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"article-number":"1362484"}}